EMPOWERING PHARMACEUTICAL COMPANIES
Utilize our solution's capacity to gather patient data in their day-to-day environment to drive your decisions and provide data-informed care.
From the moment of diagnosis, Living Well provides validated psychological support to cancer patients while restoring their well-being and quality of life. Gathering patient-reported outcomes throughout the journey, in both clinical and real-world settings, ensures better-tailored treatment and more comprehensive patient care while delivering substantial value for pharmaceutical companies.
A deeper understanding of the patient journey allows for crafting more comprehensive options for patient needs and preferences due to:
Data-driven decision making leads to optimized portfolio and product development, enhancing overall market appeal through:
Provider-centricity and leadership in innovative, comprehensive patient-care attract partners, driving new cooperation and revenue opportunities due to:
“Doing more for patients by expanding our partnerships with providers of support services that can help make a difference in patients’ lives is of the utmost importance to us. We believe that there is still a high unmet need for mental health support services and that Prosoma is the right partner to help reduce the mental burden for patients.”
Globally recognized by healthcare providers and professionals, Living Well is widely recommended to cancer patients due to its extensive benefits for both sides.
Active users after 42 days
(6 weeks)
Those who would recommend to a friend
“The Living Well app differs from the other ones because of its therapeutic and resource-oriented approach. The app is based on the evidence-based approach of cognitive behavioral therapy. It uses this standard, but goes beyond to include a variety of elements for coping with illness and strengthening personal resources.”
Living Well is currently undergoing Randomized Controlled Trials (RCT) in the US, Germany, and Poland. The program is also continuously tested through Real-World data analyses.
68%
of users with a clinically significant decrease in anxiety*
62%
of users with a clinically significant decrease in depression*
40%
of users with high baseline distress levels reduced to no risk levels in distress*
Statistically significant increase in positive emotions, and decrease in negative emotions*
*RWE analyses | **Randomized Clinical Trial; a comparison of results between the experimental group and the control group
Our Real-World-Data confirms patients' regular usage and highly positive perception of our solution.
Active users after 28 days
(4 weeks)
Active users after 42 days
(6 weeks)
Active users after 56 days
(8 weeks)
Those who would
recommend to a friend
“When patients are using Living Well App, I can see the progress and how they change and how much better they handle the adversities related to cancer treatment. Living Well promotes scientifically validated behavioural change interventions that help them follow their treatment, enjoy a healthier lifestyle and improve their quality of life.”
PATIENT TESTIMONIALS
CASE STUDY
Living Well and Daiichi-Sankyo Germany
Overview
Daiichi Sankyo partnered with Prosoma to pursue innovative, patient-centric cancer care. Together, they promoted Living Well to oncology communities through various marketing activities, including Continuing Medical Education (CME) training, where over 400 doctors participated, that focused on raising awareness on the significance of mind-body treatments for cancer patients and educating the market. Living Well's value was highlighted, emphasizing its 360-degree patient care.
The results
“Living Well's ability to engage patients in its active utilization also benefits providers, allowing them to access unique data, track patients’ mental health progress, and manage care respectively. It is, therefore, more than a mere digital solution. It has the potential to support individual patients while optimizing healthcare systems’ overall effectiveness all at the same time.”